256446-66-9

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 501-53-1 benzyl chloroformate 
• 31321-68-3 (R)-piperazine-2-carboxylic acid 

Downstream Products

• 1058723-73-1 C₂₂H₂₂N₄O₅ 
• 943816-06-6 (R)-piperazine-2-ylmethyl tert-butyldiphenylsilylether 
• 1058723-74-2 C₂₄H₂₈N₂O₆ 

Relevant academic research and scientific papers

C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS

The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.

C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS

The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.

OPTICALLY ACTIVE TRIETHYLENEDIAMINE DERIVATIVE AND METHOD FOR PRODUCING THE SAME

PROBLEM TO BE SOLVED: To provide an optically active triethylenediamine derivative useful as an asymmetric reagent and a method of producing the same. SOLUTION: An optically active (R or S)-(hydroxymethyl) triethylenediamine represented by formula (1b) (w

DIBENZO[B,F][1,4]OXAZAPINE COMPOUNDS

The present invention relates to 11-(piperazin-l-yl)dibenzo[b,f][l,4]oxazapine compounds of the formula I (I) where the variables are as defined herein, their salts and pharmaceutically acceptable compositions thereof. Methods of preparing these compounds are also described. These compounds may be used in the treatment of disorders such as schizophrenia, treatment resistant schizophrenia, bipolar disorder, psychotic depression, treatment resistant depression, schizophrenia-associated depression, treatment resistant OCD, autism, senile psychosis, psychotic dementia, L-DOPA induced psychosis, psychogenic polydipsia, psychotic symptoms of neurological disorders, sleep disorders.

FARNESYL PROTEIN TRANSFERASE INHIBITORS

Disclosed are compounds of formula (1.0), wherein R represents a cyclic moiety to which is bound an imodazolylalkyl group; R represents a carbamate, urea, amide or sulfonamide group; and the remaining substituents are as defined herein. Also disclosed is a method of treating cancer and a method of inhibiting farnesyl protein transferase using the disclosed compounds.